Review Article
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
Table 1
Drug-induced pathways and molecular targets associated with the upregulation of NKG2D and DNAM-1L expression on MM cells.
| Drug | Pathway/molecular target | Ligands | References |
| Genotoxic agents Doxorubicin Melphalan | ROS-dependent DDR | MICA/B, ULPB1-3 PVR, Nectin-2 | Soriani et al., 2009 [19]; Soriani et al., 2014 [29] |
| GSK3 inhibitors LiCl BIO SB21 | STAT3 inhibition | MICA | Fionda et al., 2013 [63] |
| Proteasome inhibitor Bortezomib | DDR | MICA, ULBP1-3, PVR, Nectin-2 | Jinushi et al., 2008 [17] Soriani et al., 2009 [19] |
| Histone deacetylase inhibitor Valproic acid | ERK | MICA/B ULBP-2 | Wu et al., 2012 [23] |
| Hsp90 inhibitors Radicicol, 17-AAG | HSR | MICA/B | Fionda et al., 2009 [22] |
|
|
DDR: DNA damage response; ROS: reactive oxygen species. HSR: heat shock response; ERK: extracellular signal-regulated kinase.
|